Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059154 | 1.00 | ACACB (0.32) | ACACBPIK3R1PIK3CARORCGPR119 | |
| SCHEMBL31059155 | 0.86 | ACACB (0.34) | ACACBPIK3R1PIK3CAGPR119MEN1 | |
| SCHEMBL31059139 | 0.86 | ACACB (0.35) | ACACBPIK3R1PIK3CAGPR119 | |
| SCHEMBL23317472 | 0.86 | ACACB (0.35) | ACACBPIK3R1PIK3CAGPR119 | |
| SCHEMBL23317063 | 0.86 | ACACB (0.34) | ACACBPIK3R1PIK3CAGPR119MEN1 | |
| SCHEMBL23304822 | 0.86 | IRAK4 (0.30) | — | |
| SCHEMBL31059151 | 0.85 | ACACB (0.33) | ACACBPIK3R1PIK3CAGPR119MEN1 | |
| SCHEMBL23317062 | 0.85 | ACACB (0.33) | ACACBPIK3R1PIK3CAGPR119MEN1 | |
| SCHEMBL23317407 | 0.85 | ACACB (0.33) | ACACBPIK3R1PIK3CAGPR119 | |
| SCHEMBL23317527 | 0.84 | GPR119 (0.33) | ACACBPIK3R1PIK3CAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-02-23 | — | — | US | disclosed |
| EP-4051682-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929709-A | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | 比奥根MA公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021086966-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060003-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MAN2A1, MAN2B2, ST6GAL1 | ACACB 1515/4885PIK3R1 3283/4885PIK3CA 2823/4885 |
| US-12565504-B2 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | MGAT3, ST6GAL1, MGAT1 | ACACB 752/4885PIK3R1 3066/4885PIK3CA 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.